BIOCIENCIAS: Bª Y CLÍNICA DEL CÁNCER Y MEDIC. TRASLACIONAL
Escuela de doctorado
Centre Hospitalier Regional et Universitaire de Lille
Lila, FranciaPublicaciones en colaboración con investigadores/as de Centre Hospitalier Regional et Universitaire de Lille (20)
2024
-
Single agent subcutaneous blinatumomab for advanced acute lymphoblastic leukemia
American Journal of Hematology, Vol. 99, Núm. 4, pp. 586-595
2023
-
Integrating biological HLA-DPB1 mismatch models to predict survival after unrelated hematopoietic cell transplantation
Haematologica
-
The p.Pro2232Leu variant in the ChEL domain of thyroglobulin gene causes intracellular transport disorder and congenital hypothyroidism
Endocrine, Vol. 80, Núm. 1, pp. 47-53
2022
-
Developing a Diagnostic Multivariable Prediction Model for Urinary Tract Cancer in Patients Referred with Haematuria: Results from the IDENTIFY Collaborative Study
European Urology Focus, Vol. 8, Núm. 6, pp. 1673-1682
2021
-
Minimal residual disease in Myeloma: Application for clinical care and new drug registration
Clinical Cancer Research, Vol. 27, Núm. 19, pp. 5195-5212
-
The IDENTIFY study: the investigation and detection of urological neoplasia in patients referred with suspected urinary tract cancer – a multicentre observational study
BJU International, Vol. 128, Núm. 4, pp. 440-450
2018
-
Azacitidine improves outcome in higher-risk MDS patients with chromosome 7 abnormalities: a retrospective comparison of GESMD and GFM registries
British Journal of Haematology, Vol. 181, Núm. 3, pp. 350-359
-
Molecular analysis of thyroglobulin mutations found in patients with goiter and hypothyroidism
Molecular and Cellular Endocrinology, Vol. 473, pp. 1-16
2017
-
Long-term survival of patients with CLL after allogeneic transplantation: A report from the European Society for Blood and Marrow Transplantation
Bone Marrow Transplantation, Vol. 52, Núm. 3, pp. 372-380
-
Romidepsin induces durable responses in patients with relapsed or refractory angioimmunoblastic T-cell lymphoma
Hematological Oncology
2016
2015
2014
-
A randomized, open-label, multicentre, phase 2/3 study to evaluate the safety and efficacy of lumiliximab in combination with fludarabine, cyclophosphamide and rituximab versus fludarabine, cyclophosphamide and rituximab alone in subjects with relapsed chronic lymphocytic leukaemia
British Journal of Haematology, Vol. 167, Núm. 4, pp. 466-477
-
Romidepsin for the treatment of relapsed/refractory peripheral T-cell lymphoma: Pivotal study update demonstrates durable responses
Journal of Hematology and Oncology, Vol. 7, Núm. 1
-
Therapeutic options in relapsed or refractory peripheral T-cell lymphoma
Cancer Treatment Reviews, Vol. 40, Núm. 9, pp. 1080-1088
2012
-
Results from a pivotal, open-label, phase II study of romidepsin in relapsed or refractory peripheral T-cell lymphoma after prior systemic therapy
Journal of Clinical Oncology, Vol. 30, Núm. 6, pp. 631-636
2007
-
A phase II multicenter study of troxacitabine in relapsed or refractory lymphoproliferative neoplasms or multiple myeloma
Leukemia and Lymphoma, Vol. 48, Núm. 1, pp. 39-45
2003
2002
-
Graft-versus-host disease and outcome in HLA-identical sibling transplantations for chronic myeloid leukemia
Blood, Vol. 100, Núm. 12, pp. 3877-3886